• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Herbalife Ltd.

    8/6/25 4:42:24 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care
    Get the next $HLF alert in real time by email
    S-8 1 ea0251902-s8_herbal.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on August 6, 2025

    Registration No. 333-       

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    HERBALIFE LTD.

    (Exact name of registrant as specified in its charter)

     

     

     

    Cayman Islands   98-0377871
    (State or Other Jurisdiction of
    Incorporation or Organization)
      (I.R.S. Employer
    Identification No.)

     

    P.O. Box 309

    Ugland House

    Grand Cayman, Cayman Islands

    KY1-1104 

    (Address of Principal Executive Offices, Zip Code)

     

    Inducement Stock Appreciation Rights

    (Full title of the plan)

     

    Henry C. Wang

    Chief Legal Officer & Corporate Secretary

    Herbalife Ltd.

    P.O. Box 309

    Ugland House

    Grand Cayman, Cayman Islands KY1-1104 

    (213) 745-0500 

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copy to:

     

    Sean Feller

    Gibson, Dunn & Crutcher LLP

    2029 Century Park East, Suite 4000

    Los Angeles, CA 90067-3026

    Telephone: (310) 552-8500 

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☒ Accelerated filer ☐
    Non-accelerated filer ☐ Smaller reporting company ☐
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    INTRODUCTION

     

    This Registration Statement on Form S-8 (this “Registration Statement”) is filed by Herbalife Ltd., a Cayman Islands exempted limited liability company (the “Registrant”), to register 750,000 shares of the Registrant’s Common Shares, par value $0.0005 per share (the “Common Shares”), that may be offered and issued in connection with employment inducement awards granted pursuant to NYSE Listed Company Manual Rule 303A.08 in the form of stand-alone stock appreciation right awards to certain award recipients as a material inducement to become employees of the Company.

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information*

     

    * Information required by Part I to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the Note to Part I of Form S-8. 

     

    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Certain Documents by Reference

     

    The following documents filed by the Registrant with the Securities and Exchange Commission (the “Commission”) are hereby incorporated by reference in this Registration Statement on Form S-8: 

     

      (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Commission on February 19, 2025;

     

      (b) The Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025 and June 30, 2025 filed with the Commission on April 30, 2025 and August 6, 2025, respectively;

     

      (c) The Registrant’s Current Reports on Form 8-K filed with the Commission on January 30, 2025, February 12, 2025, February 19, 2025 (Items 5.02 and 9.01 only), April 25, 2025 and June 16, 2025; and

     

      (d) The description of the Common Shares contained in the Registrant’s Registration Statement on Form 8-A, filed with the Commission on December 12, 2004, which incorporates by reference the description of the Common Shares contained in the Registration Statement on Form S-1 (File No. 333-119485) (originally filed with the Commission on October 1, 2004), as amended, and any amendment or report filed for the purpose of updating such description, including Exhibit 4.6 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), after the date hereof and prior to the filing of a post-effective amendment hereto which indicates that all securities offered hereunder have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement on Form S-8 and to be a part hereof from the date of filing of such documents; provided, however, unless expressly incorporated by reference into this Registration Statement on Form S-8, documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement on Form S-8. 

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement on Form S-8 to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement on Form S-8. 

     

    II-1

     

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    The Registrant’s Amended and Restated Memorandum and Articles of Association provide that, to the fullest extent permitted by law, every director and officer of the Registrant and any trustee acting in relation to the affairs of the Registrant (a “Covered Person”) shall be indemnified by the Registrant against any liability incurred by them by reason of the fact that they are or were a Covered Person, but provided that no such indemnity is given in respect of any liability arising out of a Covered Person’s fraud or dishonesty in the performance of their duty to the Registrant or a Covered Person’s conscious, intentional or willful breach of their obligation to act honestly, lawfully and in good faith with a view to the best interests of the Registrant. To the fullest extent permitted by law, no director or officer of the Registrant shall be liable to the Registrant for any loss or liability in carrying out his functions, provided that this shall not apply to any liability arising from any fraud or dishonesty of such director or officer or such director or officer’s conscious, intentional or willful breach of their obligation to act honestly, lawfully and in good faith with a view to the best interests of the Registrant, or any claims or rights of action to recover any gain, personal profit or other advantage to which such director or officer is not legally entitled.

     

    The Registrant is a Cayman Islands exempted limited liability company. As such, it is governed by the laws of the Cayman Islands with respect to the indemnification provisions. Cayman Islands law does not limit the extent to which a company’s articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. As described above, the Registrant’s Amended and Restated Memorandum and Articles of Association provide for indemnification of officers and directors, except in the case of (a) any fraud or dishonesty of such director or officer, (b) such director’s or officer’s conscious, intentional or willful breach of his obligation to act honestly, lawfully and in good faith with a view to the best interests of the Registrant and (c) any claims or rights of action to recover any gain, personal profit or other advantage to which such director or officer is not legally entitled.

     

    The Registrant has entered into an indemnification agreement with each of its directors and certain of its officers to supplement the indemnification protection available under its Amended and Restated Memorandum and Articles of Association. These indemnity agreements generally provide that the Registrant will indemnify the parties thereto to the fullest extent permitted by law.

     

    The foregoing summaries are necessarily subject to the complete text of the Amended and Restated Memorandum and Articles of Association and the indemnification agreements referred to above and are qualified in their entirety by reference thereto.

     

    In addition to the indemnification provisions set forth above, the Registrant maintains insurance policies that indemnify its directors and officers against various liabilities arising under the Securities Act of 1933, as amended, and the Exchange Act, that might be incurred by any director or officer in his capacity as such.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    II-2

     

     

    Item 8. Exhibits.

     

    Exhibit
    Number
      Description
       
    4.1   Amended and Restated Memorandum and Articles of Association of Herbalife Ltd., filed on May 2, 2023 as Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 and is incorporated herein by reference.
       
    4.2   Form of Share Certificate, filed on December 14, 2004 as Exhibit 4.3 to Amendment No. 5 to the Registrant’s Registration Statement on Form S-1 (Registration No. 333-119485) and is incorporated herein by reference.
       
    5.1*   Legal Opinion of Maples and Calder (Cayman) LLP, special Cayman Islands Counsel to Herbalife Ltd.
       
    23.1*   Consent of Maples and Calder (Cayman) LLP (contained in Exhibit 5.1).
       
    23.2*   Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.
       
    24.1*   Power of Attorney (contained on signature page hereto).
       
    99.1*   Herbalife Ltd. Form of Stock Appreciation Right Award Agreement (Inducement Award).
       
    107.1*   Filing Fee Table.

     

    * Filed herewith

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    II-3

     

     

    Provided, however, that: Paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement; and

     

    (2) That, for the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

     

    II-4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California, on August 6, 2025.

     

    HERBALIFE LTD.  
         
    By: /s/ John G. DeSimone  
    Name:  John G. DeSimone  
    Title: Chief Financial Officer  

     

    POWER OF ATTORNEY.

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature to this Registration Statement appears below hereby constitutes and appoints John G. DeSimone and Henry C. Wang, and each of them, as such person’s true and lawful attorney-in-fact and agent with full power of substitution for such person and in such person’s name, place and stead, in any and all capacities, to sign and to file with the Securities and Exchange Commission, any and all amendments and post-effective amendments to this Registration Statement (including any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought), with exhibits thereto and other documents in connection therewith, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that each said attorney-in-fact and agent, or any substitute therefor, may lawfully do or cause to be done by virtue thereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Stephan P. Gratziani   Chief Executive Officer   August 6, 2025
    Stephan P. Gratziani   (Principal Executive Officer)    
             
    /s/ John G. DeSimone   Chief Financial Officer   August 6, 2025
    John G. DeSimone   (Principal Financial Officer)    
             
    /s/ Jehangir “Bobby” Irani   Senior Vice President, Chief Accounting Officer   August 6, 2025
    Jehangir “Bobby” Irani   (Principal Accounting Officer)    
             
    /s/ Richard H. Carmona   Director   August 6, 2025
    Richard H. Carmona        
             
    /s/ Lynda Cloud   Director   August 6, 2025
    Lynda Cloud        
             
    /s/ Celine Del Genes   Director   August 6, 2025
    Celine Del Genes        
             
    /s/ Michael O. Johnson   Chairman of the Board and Director   August 6, 2025
    Michael O. Johnson        
             
    /s/ Sophie L’Hélias   Director   August 6, 2025
    Sophie L’Hélias        

     

    II-5

     

     

    /s/ Michael Levitt

      Director   August 6, 2025
    Michael Levitt        
         

    /s/ Rodica Macadrai

      Director   August 6, 2025
    Rodica Macadrai        
         

    /s/ Juan Miguel Mendoza

      Director   August 6, 2025
    Juan Miguel Mendoza        
         

    /s/ Perkins Miller

      Director   August 6, 2025
    Perkins Miller        
         

    /s/ Donal Mulligan

      Director   August 6, 2025
    Donal Mulligan        
         

    /s/ Maria Otero

      Director   August 6, 2025
    Maria Otero        

     

    II-6

     

    Get the next $HLF alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HLF

    DatePrice TargetRatingAnalyst
    3/21/2025$7.50 → $14.00Neutral → Buy
    DA Davidson
    8/1/2024$16.00 → $17.00Buy
    B. Riley Securities
    9/14/2023$13.50Neutral
    DA Davidson
    6/7/2023$13.00Neutral
    Mizuho
    2/3/2023$14.00Underperform
    BofA Securities
    7/12/2022$26.00Hold → Buy
    Jefferies
    5/17/2022Buy → Hold
    Argus
    5/4/2022$60.00 → $26.00Buy → Hold
    Jefferies
    More analyst ratings

    $HLF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mendoza Juan Miguel bought $23,572 worth of shares (3,143 units at $7.50), increasing direct ownership by 2% to 170,000 units (SEC Form 4)

    4 - HERBALIFE LTD. (0001180262) (Issuer)

    6/9/25 6:00:12 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    Director Mendoza Juan Miguel bought $33,750 worth of shares (5,000 units at $6.75), increasing direct ownership by 3% to 166,857 units (SEC Form 4)

    4 - HERBALIFE LTD. (0001180262) (Issuer)

    5/23/25 4:01:25 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    Director Mendoza Juan Miguel bought $33,650 worth of shares (5,000 units at $6.73) and was granted 21,857 shares, increasing direct ownership by 20% to 161,857 units (SEC Form 4)

    4 - HERBALIFE LTD. (0001180262) (Issuer)

    5/6/25 8:19:33 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    $HLF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Herbalife CEO and CFO to Participate in Barclays Global Consumer Staples Conference on September 2

    Herbalife Ltd. (NYSE:HLF), a premier health and wellness company, community and platform, today announced Stephan Gratziani, Chief Executive Officer, and John DeSimone, Chief Financial Officer, will participate in a fireside chat at the Barclays Global Consumer Staples Conference on Tuesday, September 2, 2025 at 4:30 p.m. ET (1:30 p.m. PT). A link to the live webcast will be available under the Investor Relations section of Herbalife's website at https://ir.herbalife.com/. A replay of the webcast will also be available at the same website following the completion of the event and for six months thereafter. About Herbalife Ltd. Herbalife (NYSE:HLF) is a premier health and wellness comp

    8/19/25 7:05:00 AM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    Herbalife Reports Q2 Net Sales Near Guidance Midpoint; Q2 Adjusted EBITDA1 Exceeds Guidance; Raises Net Sales and Adjusted EBITDA1 Full-Year Guidance

    Highlights MultiBurn™ Launch and Unveiling of Beta Version of Pro2col App and Healthy Lifespan Supplement Herbalife Ltd. (NYSE:HLF) today reported financial results for the second quarter ended June 30, 2025: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806517228/en/ "Herbalife is entering a pivotal new era. The beta release of our AI-assisted Pro2col™ app at our North America Extravaganza, with over 7,000 distributors joining this early access phase, marks a bold and powerful first step." - Stephan Gratziani, CEO Highlights Second Quarter 2025 Net sales of $1.3 billion near midpoint of guidance range Down 1.7% vs.

    8/6/25 4:10:00 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    Herbalife Launches MultiBurn™: A Science-Backed Weight Loss Supplement Supporting Metabolic Health

    New daily supplement features clinically studied botanicals to support weight loss, healthy fat reduction and energy expenditure* Herbalife Ltd. (NYSE:HLF), a premier health and wellness company, community and platform, today announced the launch of MultiBurn™ — a next-generation multi-action dietary supplement designed with clinically studied botanical extracts to support key areas of metabolic health*. Formulated by Herbalife's global team of scientists and nutrition experts, MultiBurn™ is gluten-free, suitable for vegans and made without synthetic colors or dyes, reflecting the company's commitment to clean-label, user-friendly wellness solutions. This press release features multimedi

    7/7/25 8:19:00 AM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    $HLF
    SEC Filings

    View All

    SEC Form S-8 filed by Herbalife Ltd.

    S-8 - HERBALIFE LTD. (0001180262) (Filer)

    8/6/25 4:42:24 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    Herbalife Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - HERBALIFE LTD. (0001180262) (Filer)

    8/6/25 4:26:28 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    SEC Form 10-Q filed by Herbalife Ltd.

    10-Q - HERBALIFE LTD. (0001180262) (Filer)

    8/6/25 4:15:08 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    $HLF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Herbalife Nutrition upgraded by DA Davidson with a new price target

    DA Davidson upgraded Herbalife Nutrition from Neutral to Buy and set a new price target of $14.00 from $7.50 previously

    3/21/25 8:38:07 AM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    B. Riley Securities reiterated coverage on Herbalife Nutrition with a new price target

    B. Riley Securities reiterated coverage of Herbalife Nutrition with a rating of Buy and set a new price target of $17.00 from $16.00 previously

    8/1/24 8:12:23 AM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    DA Davidson initiated coverage on Herbalife Nutrition with a new price target

    DA Davidson initiated coverage of Herbalife Nutrition with a rating of Neutral and set a new price target of $13.50

    9/14/23 7:19:53 AM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    $HLF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Johnson Michael covered exercise/tax liability with 125,849 shares, decreasing direct ownership by 13% to 814,726 units (SEC Form 4)

    4 - HERBALIFE LTD. (0001180262) (Issuer)

    9/3/25 7:00:32 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    Director Mendoza Juan Miguel bought $23,572 worth of shares (3,143 units at $7.50), increasing direct ownership by 2% to 170,000 units (SEC Form 4)

    4 - HERBALIFE LTD. (0001180262) (Issuer)

    6/9/25 6:00:12 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    Director Mendoza Juan Miguel bought $33,750 worth of shares (5,000 units at $6.75), increasing direct ownership by 3% to 166,857 units (SEC Form 4)

    4 - HERBALIFE LTD. (0001180262) (Issuer)

    5/23/25 4:01:25 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    $HLF
    Leadership Updates

    Live Leadership Updates

    View All

    Herbalife Welcomes Lynda Cloud to its Board of Directors

    Herbalife Ltd. (NYSE:HLF), a premier health and wellness company, community and platform, today announced the election of Lynda Cloud to its Board of Directors, effective April 23, 2025. This appointment reflects Herbalife's continued commitment to innovation, digital transformation, and personalized wellness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425107883/en/Herbalife Welcomes Lynda Cloud to the Board of Directors Lynda Cloud's decades of leadership across education, technology, and health sectors make her uniquely equipped to support Herbalife's next chapter. Her deep expertise in digital learning, consumer experie

    4/25/25 5:12:00 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    Herbalife Appoints Stephan Gratziani as Chief Executive Officer

    Current CEO Michael Johnson Transitions to Executive Chairman Herbalife Ltd. (NYSE:HLF) today announced its Board of Directors has appointed President, Stephan Gratziani as Chief Executive Officer (CEO) effective May 1, 2025. Michael Johnson, current CEO and Chairman of the Board, will transition to Executive Chairman. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219653469/en/Herbalife appoints Stephan Gratziani as Chief Executive Officer (Photo: Business Wire) As a former Herbalife independent distributor, Mr. Gratziani built and grew his international business into one of the top global distributorships. For 32 years, he

    2/19/25 4:05:00 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    Herbalife Expands Board of Directors with Appointment of Perkins Miller

    Herbalife Ltd. (NYSE:HLF), a premier health and wellness company, community and platform, today welcomed experienced e-commerce and media technology executive Perkins Miller to its board of directors. Miller's appointment as an independent director is effective June 26, 2024. "Perkins brings valuable, proven expertise in leading large-scale e-commerce, technology and sports enterprises, which will be a great asset to our Board as the Company continues to grow and transform," said Michael Johnson, Chairman and CEO of Herbalife. Miller is the CEO of Fandom, the world's largest fan platform where fans immerse themselves in imagined worlds across entertainment and gaming, where he has trans

    6/26/24 7:05:00 AM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    $HLF
    Financials

    Live finance-specific insights

    View All

    Herbalife Reports Q2 Net Sales Near Guidance Midpoint; Q2 Adjusted EBITDA1 Exceeds Guidance; Raises Net Sales and Adjusted EBITDA1 Full-Year Guidance

    Highlights MultiBurn™ Launch and Unveiling of Beta Version of Pro2col App and Healthy Lifespan Supplement Herbalife Ltd. (NYSE:HLF) today reported financial results for the second quarter ended June 30, 2025: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806517228/en/ "Herbalife is entering a pivotal new era. The beta release of our AI-assisted Pro2col™ app at our North America Extravaganza, with over 7,000 distributors joining this early access phase, marks a bold and powerful first step." - Stephan Gratziani, CEO Highlights Second Quarter 2025 Net sales of $1.3 billion near midpoint of guidance range Down 1.7% vs.

    8/6/25 4:10:00 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    Herbalife to Announce Second Quarter 2025 Results on August 6

    Herbalife Ltd. (NYSE:HLF), a premier health and wellness company, community and platform, will release its second quarter 2025 financial results after the close of trading on the NYSE on Wednesday, August 6, 2025. On the same day, at 5:30 p.m. ET (2:30 p.m. PT), Herbalife's senior management team will host an audio webcast and conference call to discuss its recent financial results. The audio webcast will be available at the following link: https://edge.media-server.com/mmc/p/2syhpnp7 Participants joining via the conference call may obtain the dial-in information and personal PIN to access the call by registering at the following link: https://register-conf.media-server.com/register/BI5

    7/1/25 7:05:00 AM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    Herbalife Reports Q1 Net Sales at Midpoint of Guidance Range, Net Sales Growth Excluding FX Headwinds1; Q1 Adjusted EBITDA2 Exceeds Guidance; Updates Full-Year Guidance

    Herbalife Ltd. (NYSE:HLF) today reported financial results for the first quarter ended March 31, 2025: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250430667438/en/ "Our first quarter results were strong, and we raised our full-year 2025 Adjusted EBITDA2 expectations. Our recent acquisitions strengthen our position and support our commitment to transformative growth," Stephan Gratziani, President and incoming CEO (effective May 1 '25). Highlights First Quarter 2025 Net sales of $1.2 billion at midpoint of guidance range Down 3.4% vs. Q1 ‘24 Includes 480 basis points of FX headwinds Up 1.4% year-over-year on constant cu

    4/30/25 4:10:00 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    $HLF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Herbalife Ltd.

    SC 13G/A - HERBALIFE LTD. (0001180262) (Subject)

    11/14/24 4:11:11 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by Herbalife Ltd.

    SC 13G - HERBALIFE LTD. (0001180262) (Subject)

    11/13/24 4:01:31 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Herbalife Ltd.

    SC 13G/A - HERBALIFE LTD. (0001180262) (Subject)

    11/13/24 12:49:27 PM ET
    $HLF
    Other Pharmaceuticals
    Health Care